Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
about
The potential regimen of target-controlled infusion of propofol in flexible bronchoscopy sedation: a randomized controlled trialChanges in resting neural connectivity during propofol sedationNormalizing Oral Fluid Hydrocodone Data Using Calculated Blood Volume.Acupuncture for post anaesthetic recovery and postoperative pain: study protocol for a randomised controlled trial.Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.Robust control of burst suppression for medical comaCross-simulation between two pharmacokinetic models for the target-controlled infusion of propofol.The influence of initial target effect-site concentrations of propofol on the similarity of effect-sites concentrations at loss and return of consciousness in elderly female patients with the Diprifusor system.The median effective concentration (EC50) of propofol with different doses of fentanyl during colonoscopy in elderly patients.Target-controlled versus fractionated propofol sedation in flexible bronchoscopy: A randomized noninferiority trial.Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kgFemale Patients Require a Higher Propofol Infusion Rate for Sedation.Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.The safety and efficacy of alfentanil-based induction in bronchoscopy sedation: A randomized, double-blind, controlled trial.Propofol and children--what we know and what we do not know.Automation of anaesthesia: a review on multivariable control.Total intravenous anesthesia will supercede inhalational anesthesia in pediatric anesthetic practice.Neural correlates of successful semantic processing during propofol sedation.Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation.Fentanyl-Norfentanyl Concentrations During Transdermal Patch Application: LC-MS-MS Urine Analysis.Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant.Effect of hyperglycemia on brain and liver 18F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging.Pharmacodynamic analysis of target-controlled infusion of propofol in patients with hepatic insufficiency.Effects of balanced propofol sedation on QT, corrected QT, and P-wave dispersion on upper endoscopy.Age related inverse dose relation of sedatives and analgesics in the intensive care unit.Sedation with propofol during ERCP: is the combination with esketamine more effective and safer than with alfentanil? Study protocol for a randomized controlled trialPeri-operative management of the obese surgical patient 2015: Association of Anaesthetists of Great Britain and Ireland Society for Obesity and Bariatric Anaesthesia.Robust closed-loop control of induction and maintenance of propofol anesthesia in children.Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusions.Influence of a modified propofol equilibration rate constant (k(e0)) on the effect-site concentration at loss and recovery of consciousness with the Marsh model.Perioperative management of the obese surgical patient.Precision and Bias of Target-Controlled Prolonged Propofol Infusion for General Anesthesia and Sedation in Neurosurgical Patients.Is unconsciousness simply the reverse of consciousness?The effect of remifentanil on propofol requirements to achieve loss of response to command vs. loss of response to pain.Lessons learned from closed loops in engineering: towards a multivariable approach regulating depth of anaesthesia.Pharmacokinetics and pharmacodynamics--is there anything new?Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.Safety and performance of TCI pumps in a magnetic resonance imaging environment.A hitch-hiker's guide to the intravenous PK/PD galaxy.Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves.
P2860
Q28486775-D74EEA84-349D-41EA-A239-AE4E3CDC41CDQ30993071-FDC22C35-2B99-4505-879C-52210CA749F5Q31114116-ECFE6845-B32D-4CF4-82BF-A203875D6FAAQ34469228-BBDF3620-FBB9-4E79-8757-CD5D299E1A88Q35164864-89355A95-9E1C-4B22-9583-FA24A2575C48Q35897227-8001CAAF-7ED0-4E10-BEAB-55A9A33EF44EQ35914702-7B000BDD-279D-4B83-9D8C-362F53243312Q35920940-9B1FB23B-EE4E-4458-AA0F-18CA48D029A6Q35997292-109B3BAE-87A5-4B52-8570-7C4359EB2489Q36052387-EBF4A81E-1AFF-41B7-93C6-D207D35DF74FQ36720534-DD6B654E-CEAE-439E-A4A2-5F5377BCC3F6Q36976440-65E484DF-CC2F-46F9-BB52-C1A97E6FE256Q37203893-62C52656-5011-496A-B903-D89058BADB5EQ37384101-927D15AA-3C55-4FB2-9B41-6ACF078586E5Q37810340-7EB5DBC1-6D82-49CF-9A38-C5E1D004400FQ38222877-0B26FEF0-45BC-47B9-ABBD-FD0869D6A41BQ38259932-E2684719-46FB-4769-B73A-B67AD84CA307Q38442677-A4E797D7-E9F6-48DD-B4CD-9B2D5B6C3A65Q39204266-CD1B7971-26A5-43D5-A3CB-29AC9FF2176DQ39609522-A73168F7-3945-4F2D-BD55-B8EA9E6F231FQ41130919-6311D072-2852-45E2-A53F-69BFC0583F5DQ41361061-AC552745-5F43-47BF-966F-F3F6B5434A43Q41377802-ADBB47E6-EC84-411F-8F1D-EDD85334AABDQ42318524-927D3CF3-2A71-41B4-A015-5BC635CF290FQ42366195-8A970B80-E43D-48E7-86D3-09F035171C8DQ42375156-A252DEBE-9AA5-4B2F-94E2-9E83C90D1E92Q42393159-E8B60A62-E881-4F36-84D9-FB3FE6BCAE2FQ42598963-8CA2DD21-10D4-4423-9D60-D8E3D5F73E06Q42635454-E6F82E14-EAF6-4EA9-B190-68AE59FC6E6DQ43470501-48D3DE59-12BA-44CA-A791-71D4524D0FF5Q46440837-B00A762F-9F19-416C-91CE-A10EB2928ED1Q47213786-ED14EE06-F896-4E42-8CA3-E119C5A35D0FQ47239411-8D4768FE-7592-4C08-9490-5020BDBEA278Q47341537-4E3B59B9-A83E-4B54-B754-7165B005A3ABQ47945368-1D1ECFBD-3314-47AC-98D1-CB7FE4695B71Q48206441-6B8BAFE2-B076-4E5B-A863-99E3A3A3CF01Q48224924-E21C1972-385E-4A6D-8553-CF06C61ABF85Q48224966-23CF8F79-A1C5-4AF6-9D57-3271E929D38EQ48244603-E6BAFE24-E960-4579-88C4-279A998D3404Q48293124-5A62756A-0BFE-48FF-91B8-1BFD0778FA6B
P2860
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
@en
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
@nl
type
label
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
@en
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
@nl
prefLabel
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
@en
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
@nl
P2093
P356
P1476
Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.
@en
P2093
A R Absalom
M M R F Struys
P356
10.1093/BJA/AEP143
P407
P577
2009-06-10T00:00:00Z